Inhibition by transmembrane peptides of chimeric insulin receptors

A Bennasroune1, A Gardin, C Auzan

  • 1INSERM Unit 575, Université Louis Pasteur, 5 rue Blaise Pascal, 67084, Strasbourg, France.

Insights

Transmembrane domains of epidermal growth factor (EGF) and ErbB2 receptors can inhibit receptor activation. This suggests targeting protein interactions within cell membranes offers a new therapeutic strategy for cancer.

Area of Science:

  • Molecular biology
  • Cell signaling
  • Biochemistry

Background:

  • Receptor tyrosine kinases are crucial for cell growth and development.
  • Previous studies indicated transmembrane domains of EGF and ErbB2 receptors inhibit their activation in cancer cells.

Purpose of the Study:

  • To investigate if transmembrane domains of EGF and ErbB2 receptors can inhibit chimeric insulin receptors.
  • To explore the role of transmembrane domains in erbB receptor activation and modulation.

Main Methods:

  • Transfection of cells with chimeric insulin receptors.
  • Utilizing peptides corresponding to transmembrane domains of EGF and ErbB2 receptors.
  • Employing a genetic reporter assay to assess protein self-association.

Main Results:

  • EGF and ErbB2 receptor transmembrane domain peptides inhibited autophosphorylation of chimeric insulin receptors.
  • Inhibitory effects correlated with the propensity of transmembrane domains to self-associate.
  • Demonstrated specificity in the inhibition of receptor activation.

Conclusions:

  • Transmembrane domains are integral to erbB receptor activation.
  • Inhibiting protein-protein interactions within the cell membrane can modulate receptor activity.
  • This research provides a basis for developing novel therapeutic strategies targeting receptor tyrosine kinases.

Related Concept Videos

Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...